Drug-resistant tuberculosis: Difference between revisions
From IDWiki
m (ββ) |
m (ββ) |
||
| Line 16: | Line 16: | ||
{| class="wikitable" |
{| class="wikitable" |
||
!Resistance To |
!Resistance To |
||
!Replace With |
|||
!Drug to Stop |
|||
!Drug to Add |
|||
!Regimen |
!Regimen |
||
!Total Duration |
!Total Duration |
||
|- |
|- |
||
|INH |
|||
|INH |
|INH |
||
|FQN |
|FQN |
||
| Line 27: | Line 25: | ||
|6 months from date FQN started |
|6 months from date FQN started |
||
|- |
|- |
||
|INH |
|||
|INH |
|INH |
||
|FQN |
|FQN |
||
| Line 33: | Line 30: | ||
|6 months from date FQN started |
|6 months from date FQN started |
||
|- |
|- |
||
|RMP |
|||
|RMP |
|RMP |
||
|FQN |
|FQN |
||
| Line 39: | Line 35: | ||
|18 months from date FQN started |
|18 months from date FQN started |
||
|- |
|- |
||
|RMP |
|||
|RMP |
|RMP |
||
|None |
|None |
||
| Line 45: | Line 40: | ||
|18 months from date FQN started |
|18 months from date FQN started |
||
|- |
|- |
||
|EMB |
|||
|EMB |
|EMB |
||
|None |
|None |
||
| Line 51: | Line 45: | ||
|6 months from start of therapy |
|6 months from start of therapy |
||
|- |
|- |
||
|PZA |
|||
|PZA |
|PZA |
||
|None |
|None |
||
| Line 57: | Line 50: | ||
|9 months from start of therapy |
|9 months from start of therapy |
||
|- |
|- |
||
|INH+EMB |
|||
|INH+EMB |
|INH+EMB |
||
|FQN |
|FQN |
||
| Line 63: | Line 55: | ||
|6 months from date FQN started |
|6 months from date FQN started |
||
|- |
|- |
||
|INH+PZA |
|||
|INH+PZA |
|INH+PZA |
||
|FQN |
|FQN |
||
| Line 69: | Line 60: | ||
|9 months from date FQN started |
|9 months from date FQN started |
||
|- |
|- |
||
|INH+EMB+PZA |
|||
|INH+EMB+PZA |
|INH+EMB+PZA |
||
|FQN+injectable |
|FQN+injectable |
||
Revision as of 17:58, 18 November 2022
- Mycobacterium tuberculosis infection that is resistant to both first-line drugs, isoniazid and rifampin
Classification
- Multidrug resistant tuberculosis (MDR-TB): resistance to isoniazid and rifampicin
- Extensively drug-resistant tuberculosis (XDR-TB): resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
- Totally drug-resistant tuberculosis (TDR-TB): not well-defined
Management
- 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference:
- Any first-line agents to which it is still susceptible
- A fluoroquinolone (except ciprofloxacin)
- An injectable: kanamycin, or other parenteral agent
- Other second-line agents, starting with ethionamide
- Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months
| Resistance To | Replace With | Regimen | Total Duration |
|---|---|---|---|
| INH | FQN | 6 months RMP+EMB+PZA+FQN | 6 months from date FQN started |
| INH | FQN | 2 months RMP+EMB+PZA+FQN then 4 months RMP+EMB+FQN | 6 months from date FQN started |
| RMP | FQN | 2 months daily INH+EMB+PZA+FQN then 10-16 months INH+EMB+FQN | 18 months from date FQN started |
| RMP | None | 2 months INH+EMB+PZA, then 16 months INH+EMB | 18 months from date FQN started |
| EMB | None | 2 months INH+RMP+PZA, then 4 months INH+RMP | 6 months from start of therapy |
| PZA | None | 2 months INH+RMP+EMB, then 7 months INH+RMP | 9 months from start of therapy |
| INH+EMB | FQN | 6 months daily RMP+PZA+FQN | 6 months from date FQN started |
| INH+PZA | FQN | 9 months RMP+EMB+FQN | 9 months from date FQN started |
| INH+EMB+PZA | FQN+injectable | 2 months TMP+FQN+injectable, then 7 months RMP+FQN | 9 months from date FQN started |
References
- ^ Bern-Thomas Nyangβwa, Catherine Berry, Emil Kazounis, Ilaria Motta, Nargiza Parpieva, Zinaida Tigay, Varvara Solodovnikova, Irina Liverko, Ronelle Moodliar, Matthew Dodd, Nosipho Ngubane, Mohammed Rassool, Timothy D. McHugh, Melvin Spigelman, David A.J. Moore, Koert Ritmeijer, Philipp du Cros, Katherine Fielding. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(25):2331-2343. doi:10.1056/nejmoa2117166.
